BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA network. Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. Acta Neuropathol Commun 2018;6:89. [PMID: 30193580 DOI: 10.1186/s40478-018-0594-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Lazow MA, Fuller C, Trout AT, Stanek JR, Reuss J, Turpin BK, Szabo S, Salloum R. Immunohistochemical assessment and clinical, histopathologic, and molecular correlates of membranous somatostatin type-2A receptor expression in high-risk pediatric central nervous system tumors. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.996489] [Reference Citation Analysis]
2 Huang K, Rao C, Li Q, Lu J, Zhu Z, Wang C, Tu M, Shen C, Zheng S, Chen X, Lv F. Construction and validation of a glioblastoma prognostic model based on immune-related genes. Front Neurol 2022;13:902402. [DOI: 10.3389/fneur.2022.902402] [Reference Citation Analysis]
3 Garnier L, Vidal C, Chinot O, Cohen-jonathan Moyal E, Djelad A, Bronnimann C, Bekaert L, Taillandier L, Frenel J, Langlois O, Colin P, Menei P, Dhermain F, Carpentier C, Gerazime A, Curtit E, Figarella-branger D, Dehais C, Ducray F. Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study. The Oncologist 2022. [DOI: 10.1093/oncolo/oyac023] [Reference Citation Analysis]
4 Xiao G, Gao X, Li L, Liu C, Liu Z, Peng H, Xia X, Yi X, Zhou R. An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas. J Oncol 2021;2021:3766685. [PMID: 34961815 DOI: 10.1155/2021/3766685] [Reference Citation Analysis]
5 Tollefsen SE, Jarmund AH, Ytterhus B, Salvesen Ø, Mjønes P, Torp SH. Somatostatin Receptors in Human Meningiomas-Clinicopathological Aspects. Cancers (Basel) 2021;13:5704. [PMID: 34830858 DOI: 10.3390/cancers13225704] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Chai RC, Chang YZ, Chang X, Pang B, An SY, Zhang KN, Chang YH, Jiang T, Wang YZ. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma. J Hematol Oncol 2021;14:109. [PMID: 34246306 DOI: 10.1186/s13045-021-01124-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 32.0] [Reference Citation Analysis]
7 Mirchia K, Richardson TE. Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas. Cancers (Basel) 2020;12:E1817. [PMID: 32640746 DOI: 10.3390/cancers12071817] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 12.5] [Reference Citation Analysis]
8 Ehrstedt C, Ahlsten G, Strömberg B, Lindskog C, Casar-Borota O. Somatostatin receptor expression and mTOR pathway activation in glioneuronal tumours of childhood. Seizure 2020;76:123-30. [PMID: 32062323 DOI: 10.1016/j.seizure.2020.01.011] [Reference Citation Analysis]